A randomized, double-blind crossover study to evaluate the absorption of Rho Nutrition formulations compared to a standard comparator in healthy adults
Evaluating absorption of investigational formulations against standard formulations in healthy volunteers
There are 3 arms in this study: - Arm 1: Participants will receive a single dose of 1000mg standard vitamin C and 1000mg Rho Nutrition vitamin C. As this study is a cross-over the participants will receive both study products, the order the participant's receive the study products will be randomised. - Arm 2: Participants will receive a single dose of 100mg standard CoQ10 and 100mg Rho Nutrition CoQ10. As this study is a cross-over the participants will receive both study products, the order the participant's receive the study products will be randomised. - Arm 3: Participants will receive a single dose of standard Curcumin (200mg curcuminoids) + Resveratrol (75mg) and Rho Nutrition Curcumin (200mg curcuminoids) + Resveratrol (75mg). As this study is a cross-over the participants will receive both study products, the order the participant's receive the study products will be randomised. For each study arm the participants will come in to receive the study product on day 1 and return for a follow up on day 2, there will then be a minimum of 7 days wash out and the participants will return to receive the second assigned study product on day 1 and return for a follow up on day 2. For randomisation we will use sealed envelope.
1. Adults aged 18-50 years 2. BMI 18.5-30.0 kg/m² 3. Able to provide informed consent 4. Agree not to participate in another clinical trial while enrolled in this trial 5. Agree not to change current diet and/or exercise frequency or intensity during the entire study period 6. Females using a prescribed form of birth control (e.g. oral contraceptive) 7. Ability to participate fully and comply with the demands of the study, including attendance at all scheduled blood collection time points
1. Have a serious illness e.g. mood disorders such as depression, anxiety or bipolar disorder, neurological disorders such as MS, kidney disease, liver disease, gallbladder disease or heart conditions 2. Have an unstable illness e.g. diabetes and thyroid gland dysfunction 3. Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapy treatment for malignancy within the previous 2 years 4. Significant change in diet in the past 1 month (e.g. removal of a food group or calorie restriction) 5. Active smokers, nicotine use or drug (prescription or illegal substances) abuse 6. Chronic past and/or current alcohol use (>21 alcoholic drinks per week) 7. Pregnant or lactating women 8. Allergic to any of the ingredients in the enhanced or standard formula 9. Participants who are currently participating in any other clinical trial or who have participated in any other clinical trial during the past 1 month (excluding RDC clinical trials) 10. Any condition which, in the opinion of the investigator, makes the participant unsuitable for inclusion 11. Currently taking Coumadin (warfarin), heparin, dalteparin, enoxaparin or other anticoagulation therapy including low-dose aspirin, or any other medicine or supplement that may interact with the study product 12. Regular use within the past 14 days of supplements containing the trial product 13. Have any condition that may interfere with the absorption, metabolism or excretion of the study product, e.g. Crohn's disease